Total Payments
$5,115
2024 Payments
$1,646
Companies
30
Transactions
340
Medicare Patients
10,557
Medicare Billing
$474,939
Payment Breakdown by Category
Food & Beverage$5,115 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,115 | 340 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $908.94 | 80 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $776.60 | 42 | $0 (2024) |
| Lilly USA, LLC | $688.68 | 47 | $0 (2024) |
| Amgen Inc. | $418.22 | 24 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $331.49 | 22 | $0 (2024) |
| PFIZER INC. | $233.59 | 18 | $0 (2024) |
| Abbott Laboratories | $227.41 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $186.45 | 9 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $166.61 | 11 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $156.53 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,646 | 100 | AstraZeneca Pharmaceuticals LP ($374.86) |
| 2023 | $1,479 | 96 | ABBVIE INC. ($294.81) |
| 2022 | $922.94 | 67 | ABBVIE INC. ($214.05) |
| 2021 | $1,067 | 77 | AbbVie Inc. ($260.67) |
All Payment Transactions
340 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/19/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $28.51 | General |
| Category: Genetic Disease | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Gastroenterology | ||||||
| 12/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $7.90 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: VACCINE | ||||||
| 11/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.96 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Inflammation | ||||||
| 10/30/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Gastroenterology | ||||||
| 10/25/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: DIABETES | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/11/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: VACCINE | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Gastroenterology | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: DIABETES | ||||||
| 10/04/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/03/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Inflammation | ||||||
| 09/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: DIABETES | ||||||
| 09/09/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 2,331 | 5,806 | $396,413 | $122,704 |
| 2022 | 40 | 2,629 | 5,574 | $431,404 | $131,069 |
| 2021 | 38 | 2,927 | 5,354 | $408,423 | $129,305 |
| 2020 | 38 | 2,670 | 3,829 | $330,531 | $91,860 |
Total Patients
10,557
Total Services
20,563
Medicare Billing
$474,939
Procedure Codes
152
All Medicare Procedures & Services
152 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 1,740 | $43,500 | $31,851 | 73.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 175 | 315 | $76,955 | $23,140 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 263 | 400 | $69,850 | $19,855 | 28.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 65 | 65 | $14,300 | $6,524 | 45.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 78 | 83 | $8,300 | $4,173 | 50.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 115 | 221 | $19,006 | $3,623 | 19.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 187 | 416 | $8,424 | $3,494 | 41.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 20 | 20 | $7,900 | $3,469 | 43.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 173 | 314 | $32,970 | $3,233 | 9.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 113 | 205 | $18,450 | $2,668 | 14.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 19 | 19 | $5,320 | $2,559 | 48.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 174 | 315 | $15,120 | $2,385 | 15.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 26 | 26 | $1,970 | $1,867 | 94.8% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 54 | 110 | $4,950 | $1,784 | 36.0% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 12 | 22 | $4,400 | $1,443 | 32.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 103 | 157 | $6,673 | $1,331 | 20.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 28 | 37 | $9,250 | $1,050 | 11.3% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 55 | 100 | $6,100 | $943.80 | 15.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 25 | 27 | $4,185 | $869.33 | 20.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 159 | 279 | $7,812 | $862.67 | 11.0% |
| 87088 | Bacterial urine culture | Office | 2023 | 71 | 104 | $4,368 | $824.72 | 18.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 26 | 26 | $910.00 | $767.26 | 84.3% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 19 | 31 | $3,410 | $767.13 | 22.5% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 28 | 28 | $2,212 | $529.76 | 23.9% |
| 87186 | Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution | Office | 2023 | 38 | 61 | $3,538 | $517.27 | 14.6% |
About Kyle Jones, FNP-C
Kyle Jones, FNP-C is a Family healthcare provider based in Wake Village, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2016. The National Provider Identifier (NPI) number assigned to this provider is 1639620271.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kyle Jones, FNP-C has received a total of $5,115 in payments from pharmaceutical and medical device companies, with $1,646 received in 2024. These payments were reported across 340 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($5,115).
As a Medicare-enrolled provider, Jones has provided services to 10,557 Medicare beneficiaries, totaling 20,563 services with total Medicare billing of $474,939. Data is available for 4 years (2020–2023), covering 152 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Wake Village, TX
- Active Since 10/19/2016
- Last Updated 01/06/2017
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1639620271
Products in Payments
- FARXIGA (Drug) $480.69
- JARDIANCE (Drug) $430.16
- VRAYLAR (Drug) $421.59
- UBRELVY (Drug) $266.11
- QULIPTA (Drug) $221.24
- FREESTYLE LIBRE 3 (Device) $212.91
- BREZTRI (Drug) $209.45
- Otezla (Drug) $199.90
- XIFAXAN (Drug) $166.61
- ELIQUIS (Drug) $165.66
- EMGALITY (Drug) $161.24
- XARELTO (Drug) $156.53
- MOUNJARO (Drug) $153.76
- LEQVIO (Drug) $130.11
- Kerendia (Drug) $124.93
- TRULICITY (Drug) $117.60
- ZEPBOUND (Drug) $113.13
- VOQUEZNA (Drug) $108.88
- EVENITY (Biological) $104.26
- Ozempic (Drug) $84.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.